1 Department of psychiatry, Kohnodai Hospital, National Center for Global health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba, Japan
2 Graduate School of Education, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba, Japan
3 Psilocybe Inc., 237 Sano, Higashi-Ohmi, Shiga, Japan
4 Department of Psychiatric Rehabilitation, National Center of Neurology and Psychiatry Japan, 4-1-1 Ogawahigashicho, Kodaira, Tokyo, Japan
The purpose of the present one-year follow-up study was to describe and investigate the change in the amount of antipsychotic drugs prescribed for ACT (assertive community treatment) clients in Japan. Subjects were 52 clients of ACT from January 2009 to December 2009. Prescription data were collected each month from the time the clients entered into ACT. The results of a Wilcoxon signed-rank test show that the dosage of antipsychotics significantly decreased from 1,131.3 mg to 731.3 mg over the course of the 12 months (Z = -2.505, p = 0.012).
Keywords: Antipsychotics, Assertive Community Treatment, Medication, Japan, Schizophrenia, Community.
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
* Address correspondence to this author at the 237 Sano, Higashi-Ohmi, Shiga, 521-1222, Japan; Tel: +81-90-6136-8580; Fax: +81-748-42-2695; E-mail: firstname.lastname@example.org